DK2070530T3 - Behandling af sygdomme forbundet med anvendelse af antibiotika - Google Patents

Behandling af sygdomme forbundet med anvendelse af antibiotika Download PDF

Info

Publication number
DK2070530T3
DK2070530T3 DK09156339.5T DK09156339T DK2070530T3 DK 2070530 T3 DK2070530 T3 DK 2070530T3 DK 09156339 T DK09156339 T DK 09156339T DK 2070530 T3 DK2070530 T3 DK 2070530T3
Authority
DK
Denmark
Prior art keywords
antibiotics
treatment
compound
diseases related
resistant
Prior art date
Application number
DK09156339.5T
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2070530T3 publication Critical patent/DK2070530T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DK09156339.5T 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika DK2070530T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14
EP05748007A EP1765312B1 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number Publication Date
DK2070530T3 true DK2070530T3 (da) 2016-05-17

Family

ID=35428857

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10075449.8T DK2305244T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika
DK10075450.6T DK2305245T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelsen af antibiotika
DK09156339.5T DK2070530T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10075449.8T DK2305244T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelse af antibiotika
DK10075450.6T DK2305245T3 (da) 2004-05-14 2005-05-13 Behandling af sygdomme forbundet med anvendelsen af antibiotika

Country Status (17)

Country Link
US (2) US20070173462A1 (da)
EP (4) EP1765312B1 (da)
JP (2) JP5734545B2 (da)
AT (1) ATE516024T1 (da)
BR (1) BRPI0511119A (da)
CA (2) CA2776682A1 (da)
CY (2) CY1117501T1 (da)
DK (3) DK2305244T3 (da)
ES (4) ES2608046T3 (da)
HU (3) HUE043945T2 (da)
LT (1) LT2305245T (da)
MX (2) MX344601B (da)
PL (3) PL2070530T3 (da)
PT (2) PT2305245T (da)
SI (2) SI2070530T1 (da)
TR (1) TR201902533T4 (da)
WO (1) WO2005112990A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
MX2007009196A (es) * 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.
CA2626698C (en) * 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
WO2009117310A2 (en) * 2008-03-17 2009-09-24 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
WO2011044208A1 (en) * 2009-10-06 2011-04-14 Scott Dorfner Antibiotic formulations providing reduced gastrointentestinal side effects
US20120225889A1 (en) * 2009-11-17 2012-09-06 Piramal Life Sciences Limited Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
US9138441B2 (en) 2009-12-31 2015-09-22 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
MX2012013374A (es) * 2010-05-18 2013-05-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
UA122203C2 (uk) 2014-05-09 2020-10-12 Астеллас Фарма Юроп Лтд Схема лікування із застосуванням сполуки тіакуміцину

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (da) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
MXPA04009418A (es) * 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7507564B2 (en) 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
WO2005112990A3 (en) 2006-01-05
US20070173462A1 (en) 2007-07-26
SI2305245T1 (sl) 2019-04-30
ES2565609T3 (es) 2016-04-05
EP2070530A1 (en) 2009-06-17
EP2305245A1 (en) 2011-04-06
CY1121284T1 (el) 2020-05-29
CA2776682A1 (en) 2005-12-01
EP1765312A2 (en) 2007-03-28
HUE031581T2 (en) 2017-07-28
ATE516024T1 (de) 2011-07-15
PL2305244T3 (pl) 2017-04-28
CY1117501T1 (el) 2017-04-26
JP2012197309A (ja) 2012-10-18
MX344601B (es) 2016-12-20
TR201902533T4 (tr) 2019-03-21
EP2070530B1 (en) 2016-02-17
BRPI0511119A (pt) 2007-11-27
DK2305244T3 (da) 2017-01-30
SI2070530T1 (sl) 2016-05-31
EP1765312B1 (en) 2011-07-13
LT2305245T (lt) 2019-03-12
HUE043945T2 (hu) 2019-09-30
EP2305244B1 (en) 2016-10-12
ES2608046T3 (es) 2017-04-05
DK2305245T3 (da) 2019-03-25
EP1765312A4 (en) 2007-08-22
PT2305245T (pt) 2019-03-19
MXPA06013245A (es) 2007-05-09
WO2005112990A2 (en) 2005-12-01
PL2070530T3 (pl) 2016-06-30
HUE027757T2 (en) 2016-11-28
PT2305244T (pt) 2016-12-29
ES2713954T3 (es) 2019-05-24
ES2395404T3 (es) 2013-02-12
JP6101010B2 (ja) 2017-03-22
CA2566687C (en) 2012-07-24
JP5734545B2 (ja) 2015-06-17
PL2305245T3 (pl) 2019-05-31
JP2007537290A (ja) 2007-12-20
EP2305244A1 (en) 2011-04-06
CA2566687A1 (en) 2005-12-01
US20130274175A1 (en) 2013-10-17
EP2305245B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
CY1121284T1 (el) Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
DK2024367T3 (da) Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
GT200600114A (es) Derivados de ciclopropanocarboxamida
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
BRPI0619153B8 (pt) derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DOP2006000268A (es) Agentes antibacterianos
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
BRPI0614456B8 (pt) 8-metoxi-9h-isotiazol[5,4-b]quinolina-3,4-dionas e compostos relacionados como agentes antiinfecciosos
CY1108196T1 (el) Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα
EA201190095A1 (ru) Производные актагардина
EA200701734A1 (ru) Новые изотиазолохинолоны и родственные им соединения как антиинфекционные средства
BRPI0615614A2 (pt) compostos orgánicos
GT200700105A (es) Inhibidor del factor xa
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
MX2011011618A (es) Agentes terapeuticos 713.
BRPI0413349A (pt) compostos de oxazol para o tratamento de doenças neurodegenerativas
DE602004028113D1 (de) Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
CL2007001629A1 (es) Compuestos derivados de oximilo macrociclico, inhibidores de proteasa de hepatitis c; composicion farmaceutica, util para el tratamiento de infeccion por hepatitis c.
WO2008010070A3 (en) Novel oxazolidinone derivatives